Nanomaterials for Drug Delivery to the Central Nervous System.
| Title: | Nanomaterials for Drug Delivery to the Central Nervous System. |
|---|---|
| Authors: | Teleanu DM; Emergency University Hospital, Bucharest, Romania, 'Carol Davila' University of Medicine and Pharmacy, 050474 Bucharest, Romania. daniel.teleanu@umfcd.ro.; Negut I; National Institute for Lasers, Plasma, and Radiation Physics, RO-77125 Magurele, Romania. negut.irina@inflpr.ro.; Faculty of Physics, University of Bucharest, 077125 Magurele, Romania. negut.irina@inflpr.ro.; Grumezescu V; National Institute for Lasers, Plasma, and Radiation Physics, RO-77125 Magurele, Romania. valentina_grumezescu@yahoo.com.; Grumezescu AM; Faculty of Applied Chemistry and Materials Science, Politehnica University of Bucharest, 011061 Bucharest, Romania. grumezescu@yahoo.com.; ICUB-Research Institute of University of Bucharest, University of Bucharest, 36-46 M. Kogalniceanu Blvd., 050107 Bucharest, Romania. grumezescu@yahoo.com.; Teleanu RI; 'Victor Gomoiu' Clinical Children's Hospital, 'Carol Davila' University of Medicine and Pharmacy, 050474 Bucharest, Romania. raluca.teleanu@umfcd.ro. |
| Source: | Nanomaterials (Basel, Switzerland) [Nanomaterials (Basel)] 2019 Mar 05; Vol. 9 (3). Date of Electronic Publication: 2019 Mar 05. |
| Publication Type: | Journal Article; Review |
| Language: | English |
| Journal Info: | Publisher: MDPI AG Country of Publication: Switzerland NLM ID: 101610216 Publication Model: Electronic Cited Medium: Print ISSN: 2079-4991 (Print) Linking ISSN: 20794991 NLM ISO Abbreviation: Nanomaterials (Basel) Subsets: PubMed not MEDLINE |
| Imprint Name(s): | Original Publication: Basel, Switzerland : MDPI AG, [2011]- |
| Abstract: | The intricate microstructure of the blood-brain barrier (BBB) is responsible for the accurate intrinsic regulation of the central nervous system (CNS), in terms of neuronal pathophysiological phenomena. Any disruption to the BBB can be associated with genetic defects triggering or with local antigenic invasion (either neurotoxic blood-derived metabolites and residues or microbial pathogens). Such events can be further related to systemic inflammatory or immune disorders, which can subsequently initiate several neurodegenerative pathways. Any degenerative process related to the CNS results in progressive and yet incurable impairment of neuronal cells. Since these particular neurons are mostly scanty or incapable of self-repair and regeneration processes, there is tremendous worldwide interest in novel therapeutic strategies for such specific conditions. Alzheimer's and Parkinson's diseases (AD and PD, respectively) are conditions found worldwide, being considered the most rampant degenerative pathologies related to CNS. The current therapy of these conditions, including both clinical and experimental approaches, mainly enables symptom management and subsidiary neuronal protection and even less disease regression. Still, a thorough understanding of the BBB pathophysiology and an accurate molecular and sub-molecular management of AD and PD will provide beneficial support for more specific and selective therapy. Since nanotechnology-derived materials and devices proved attractive and efficient platforms for modern biomedicine (including detection, imaging, diagnosis, medication, restoration and regeneration), a particular approach for AD and PD management relies on nanoparticle-based therapy. In this paper we will discuss relevant aspects related to the BBB and its impact on drug-based treatment and emphasize that nanoparticles are suitable and versatile candidates for the development of novel and performance-enhanced nanopharmaceuticals for neurodegenerative conditions therapy. |
| References: | Pharm Sci Technolo Today. 2000 May;3(5):155-162. (PMID: 10785657); Proc Natl Acad Sci U S A. 2000 Jun 20;97(13):7567-72. (PMID: 10840060); J Neurochem. 2001 Feb;76(4):1121-8. (PMID: 11181832); Science. 2002 Jul 19;297(5580):353-6. (PMID: 12130773); J Neurosci. 2003 Jan 1;23(1):29-33. (PMID: 12514198); Vascul Pharmacol. 2002 Jun;38(6):323-37. (PMID: 12529927); J Control Release. 2003 Feb 21;87(1-3):187-98. (PMID: 12618035); J Cell Biol. 2003 May 12;161(3):653-60. (PMID: 12743111); J Pharm Pharm Sci. 2003 May-Aug;6(2):252-73. (PMID: 12935438); J Control Release. 2003 Dec 12;93(3):271-82. (PMID: 14644577); Mol Interv. 2003 Mar;3(2):90-105, 51. (PMID: 14993430); Curr Pharm Des. 2004;10(12):1365-70. (PMID: 15134487); Pharmacol Ther. 2004 Oct;104(1):29-45. (PMID: 15500907); NeuroRx. 2005 Jan;2(1):54-62. (PMID: 15717057); Brain Res. 2005 Mar 21;1038(2):208-15. (PMID: 15757636); Mol Biotechnol. 2005 May;30(1):57-70. (PMID: 15805577); Cell Mol Neurobiol. 2005 Feb;25(1):5-23. (PMID: 15962506); Pharm Res. 2005 Jul;22(7):1011-37. (PMID: 16028003); Circ Res. 2005 Sep 16;97(6):512-23. (PMID: 16166562); Curr Drug Deliv. 2004 Oct;1(4):361-76. (PMID: 16305398); Drug Metab Dispos. 2006 Jun;34(6):955-60. (PMID: 16510542); J Drug Target. 2006 May;14(4):191-214. (PMID: 16777679); Clin Ther. 2007 Sep;29(9):1825-49. (PMID: 18035186); Expert Opin Drug Deliv. 2008 Feb;5(2):155-74. (PMID: 18248316); Eur J Pharm Biopharm. 2008 Sep;70(1):75-84. (PMID: 18472255); Int J Nanomedicine. 2008;3(1):21-9. (PMID: 18488413); Eur J Pharm Sci. 2008 Oct 2;35(3):161-74. (PMID: 18656534); Angew Chem Int Ed Engl. 2009;48(5):872-97. (PMID: 19142939); Acta Neuropathol. 2009 Jul;118(1):103-13. (PMID: 19319544); Biochim Biophys Acta. 2010 Jan;1803(1):20-8. (PMID: 19374923); BMC Neurol. 2009 Jun 12;9 Suppl 1:S3. (PMID: 19534732); Neurobiol Dis. 2010 Jan;37(1):48-57. (PMID: 19664710); Neurobiol Dis. 2010 Jan;37(1):13-25. (PMID: 19664713); Science. 1990 Jun 1;248(4959):1120-2. (PMID: 1971458); Immunity. 2009 Nov 20;31(5):722-35. (PMID: 19836264); J Control Release. 2010 Feb 15;141(3):320-7. (PMID: 19874859); Proc Natl Acad Sci U S A. 2010 Jan 19;107(3):1235-40. (PMID: 20080552); Ann N Y Acad Sci. 2010 Jan;1184:154-72. (PMID: 20146696); Drug Metab Dispos. 2010 Aug;38(8):1355-61. (PMID: 20427691); Nature. 2010 Nov 25;468(7323):557-61. (PMID: 20944627); PLoS One. 2010 Dec 17;5(12):e15349. (PMID: 21179415); Cold Spring Harb Perspect Biol. 2011 Feb 01;3(2):null. (PMID: 21421915); Acta Neuropathol. 2011 Jul;122(1):1-9. (PMID: 21656168); Mol Neurodegener. 2011 Sep 22;6:65. (PMID: 21939532); J Cereb Blood Flow Metab. 2012 Feb;32(2):264-77. (PMID: 22044867); Nanomedicine (Lond). 2012 Jan;7(1):65-78. (PMID: 22191778); Metab Brain Dis. 2012 Mar;27(1):1-5. (PMID: 22193538); Cancer Res. 2012 Jul 15;72(14):3652-63. (PMID: 22552291); Cereb Cortex. 2013 Sep;23(9):2118-26. (PMID: 22776675); Mol Neurodegener. 2012 Sep 28;7:49. (PMID: 23017109); J Control Release. 2012 Nov 28;164(1):49-57. (PMID: 23063548); Lancet Neurol. 2013 Feb;12(2):207-16. (PMID: 23332364); PLoS One. 2013;8(1):e54182. (PMID: 23372682); Adv Nutr. 2013 Mar 01;4(2):176-90. (PMID: 23493534); Proc Natl Acad Sci U S A. 2013 May 21;110(21):8662-7. (PMID: 23650374); Curr Pharm Des. 2014;20(10):1422-49. (PMID: 23789948); J Neurochem. 1990 Oct;55(4):1222-30. (PMID: 2398356); J Nanobiotechnology. 2013 Sep 23;11:32. (PMID: 24059692); Nat Rev Neurol. 2013 Dec;9(12):677-86. (PMID: 24217510); Front Pharmacol. 2013 Nov 15;4:140. (PMID: 24298256); ACS Nano. 2014 Jan 28;8(1):76-103. (PMID: 24467380); Int J Mol Sci. 2014 Jan 24;15(2):1812-25. (PMID: 24469316); ACS Nano. 2014 Mar 25;8(3):2345-59. (PMID: 24527692); J Control Release. 2014 May 28;182:99-110. (PMID: 24631863); ACS Nano. 2014 Mar 25;8(3):1958-65. (PMID: 24660817); Int J Nanomedicine. 2014 May 10;9:2241-57. (PMID: 24872687); Expert Opin Pharmacother. 2014 Sep;15(13):1955-60. (PMID: 25085661); Eur J Pharm Biopharm. 2014 Nov;88(3):586-93. (PMID: 25173087); Pharmaceutics. 2014 Nov 17;6(4):557-83. (PMID: 25407801); Neurotherapeutics. 2015 Jan;12(1):143-50. (PMID: 25421001); J Cereb Blood Flow Metab. 2015 Mar;35(3):469-75. (PMID: 25492116); Front Neurosci. 2014 Dec 03;8:392. (PMID: 25520612); Life Sci. 2015 Mar 1;124:136-43. (PMID: 25640758); Semin Cell Dev Biol. 2015 Feb;38:2-6. (PMID: 25681530); ACS Chem Neurosci. 2015 Apr 15;6(4):505-6. (PMID: 25873191); Chem Biol Drug Des. 2015 Nov;86(5):1203-14. (PMID: 25976552); Nanomedicine (Lond). 2015;10(11):1735-50. (PMID: 26080696); Biomater Sci. 2016 Feb;4(2):219-29. (PMID: 26646694); Nat Rev Drug Discov. 2016 Apr;15(4):275-92. (PMID: 26794270); Lancet. 2016 Jul 30;388(10043):505-17. (PMID: 26921134); Nat Nanotechnol. 2016 Mar;11(3):206-10. (PMID: 26936811); Expert Opin Drug Deliv. 2016 Jul;13(7):963-75. (PMID: 27020469); J Control Release. 2016 Aug 10;235:34-47. (PMID: 27208862); J Neuroimmune Pharmacol. 2017 Mar;12(1):107-119. (PMID: 27209050); Expert Opin Drug Metab Toxicol. 2016 Sep;12(9):1021-33. (PMID: 27267126); Drug Discov Today Technol. 2016 Jun;20:41-48. (PMID: 27986222); Theranostics. 2017 Jan 1;7(2):344-356. (PMID: 28042339); J Neuroimmune Pharmacol. 2017 Mar;12(1):1-5. (PMID: 28150132); Trends Neurosci. 2017 Mar;40(3):151-166. (PMID: 28190529); Eur J Pharm Sci. 2017 May 30;103:5-18. (PMID: 28263915); Bioimpacts. 2016;6(4):225-248. (PMID: 28265539); Front Aging Neurosci. 2017 Apr 04;9:83. (PMID: 28420982); Nature. 1987 Feb 19-25;325(6106):733-6. (PMID: 2881207); Int J Nanomedicine. 2017 Oct 05;12:7291-7309. (PMID: 29042776); Small. 2018 Jan;14(3):. (PMID: 29134771); J Trace Elem Med Biol. 2018 Sep;49:210-221. (PMID: 29325805); ACS Nano. 2018 Feb 27;12(2):1321-1338. (PMID: 29364648); Int J Nanomedicine. 2018 Jan 09;13:273-281. (PMID: 29391788); Nanomedicine. 2018 Feb 21;14(4):1123-1136. (PMID: 29474924); Science. 1987 Feb 20;235(4791):880-4. (PMID: 2949367); J Nanobiotechnology. 2018 Mar 27;16(1):32. (PMID: 29587747); Int J Pharm. 2018 Jun 10;544(1):265-277. (PMID: 29689367); Drug Deliv. 2018 Nov;25(1):1091-1102. (PMID: 30107760); ACS Appl Mater Interfaces. 2018 Oct 3;10(39):32965-32980. (PMID: 30192126); Proc Natl Acad Sci U S A. 1985 Jun;82(12):4245-9. (PMID: 3159021); J Pharmacol Exp Ther. 1988 Jun;245(3):816-22. (PMID: 3385643); Brain. 1969 Mar;92(1):147-56. (PMID: 4237656); Biochem Biophys Res Commun. 1984 Aug 16;122(3):1131-5. (PMID: 6236805); J Med Chem. 1980 Jun;23(6):682-4. (PMID: 7392035); J Pharmacol Exp Ther. 1997 Sep;282(3):1541-6. (PMID: 9316870); Neurosurgery. 1998 May;42(5):1083-99; discussion 1099-100. (PMID: 9588554); J Cereb Blood Flow Metab. 1998 Nov;18(11):1270-81. (PMID: 9809517) |
| Contributed Indexing: | Keywords: Alzheimer’s disease; Parkinson’s disease; blood brain barrier; nanoparticles; neurodegenerative disease |
| Entry Date(s): | Date Created: 20190308 Latest Revision: 20201001 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC6474019 |
| DOI: | 10.3390/nano9030371 |
| PMID: | 30841578 |
| Database: | MEDLINE |
Journal Article; Review